½ÃÀ庸°í¼­
»óǰÄÚµå
1090089

¼¼°èÀÇ ¼öÀÇ Á¾¾çÇÐ ½ÃÀå : Ä¡·á¹ýº°, µ¿¹° Á¾·ùº°, ¾Ï Á¾·ùº°, Áö¿ªº° ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2022-2028³â)

Global Veterinary Oncology Market Size study, by Therapy by Animal type by Cancer Type and Regional Forecasts 2022-2028

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Bizwit Research & Consulting LLP | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ ¼öÀÇ Á¾¾çÇÐ ½ÃÀå ±Ô¸ð´Â 2021³â¿¡ ¾à 2¾ï 750¸¸ ´Þ·¯¸¦ ±â·ÏÇϰí, 2022-2028³â ¿¹Ãø±â°£ Áß 12.1% ÀÌ»óÀÇ °ÇÀüÇÑ ¼ºÀå·ü·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

½ÃÀåÀ» °ßÀÎÇϰí ÀÖ´Â °ÍÀº ¾Ö¿Ïµ¿¹°ÀÇ ¾ÏÀÌȯÀ² »ó½Â°ú Ä¡·á Àü·«À¸·Î¼­ÀÇ µ¿¹°¿ë ¾Ï Ä¡·á º¸±ÞÀÔ´Ï´Ù. ¶ÇÇÑ ¾Ï ¹ß»ýÀ» Á¤·®È­Çϱâ À§Çؼ­ °³ ¾Ï µî·ÏÀÌ ¼¼°èÀûÀ¸·Î ÇàÇØÁö°í ÀÖ´Â Á¡µµ ½ÃÀå È®´ëÀÇ ¿äÀÎÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÁÖÀÎÀÇ ¾Ö¿Ïµ¿¹° ÇコÄɾ ´ëÇÑ ÁöÃâ ÀÇ¿å »ó½ÂÀ̳ª Á¤ºÎÀÇ ¼öÀÇ ¾Ï Ä¡·á¿¡ ´ëÇÑ ´ëó¿¡ ÀÇÇØ ½ÅÈï °æÁ¦ ±¹°¡¿¡¼­ µ¿¹° ÇコÄɾ ´ëÇÑ ÁöÃâÀÌ Áõ°¡Çϰí ÀÖ´Â Á¡µµ ½ÃÀå ¼ºÀåÀ» ÁöÁöÇϰí ÀÖ½À´Ï´Ù. ±×·¯³ª µ¿¹°¿ë ¾Ï Ä¡·á¿¡ µå´Â ³ôÀº ºñ¿ëÀ̳ª Å»¸ð, ½Ä¿å ÀúÇÏ, ±¸Åä µî Á¾¾ç Ä¡·áÁ¦ÀÇ ºÎÀÛ¿ëÀÌ ¿¹Ãø±â°£ Áß ½ÃÀå È®´ë¸¦ ÀúÇØÇÒ °ÍÀ¸·Î »ý°¢µË´Ï´Ù.

¼¼°èÀÇ ¼öÀÇ Á¾¾çÇÐ(Veterinary Oncology) ½ÃÀå¿¡ ´ëÇØ Á¶»ç ºÐ¼®ÇßÀ¸¸ç, ½ÃÀå µ¿Çâ, ¾÷°è ºÐ¼®, COVID-19ÀÇ ¿µÇâ, ºÎ¹®º°¡¤Áö¿ªº° ½ÃÀå ºÐ¼®, ±â¾÷ °³¿ä µîÀ» Á¦°øÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ¼¼°èÀÇ ¼öÀÇ Á¾¾çÇÐ ½ÃÀå Á¤ÀÇ¿Í ¹üÀ§

Á¦3Àå ¼¼°èÀÇ ¼öÀÇ Á¾¾çÇÐ ½ÃÀå ¿ªÇÐ

  • ¼öÀÇ Á¾¾çÇÐ ½ÃÀåÀÇ ¿µÇ⠺м®(2020-2028³â)

Á¦4Àå ¼¼°èÀÇ ¼öÀÇ Á¾¾çÇÐ ½ÃÀå ¾÷°è ºÐ¼®

  • Porter's 5 Force ¸ðµ¨
  • PEST ºÐ¼®
  • ÅõÀÚ Ã¤¿ë ¸ðµ¨
  • ¾Ö³Î¸®½ºÆ®ÀÇ Ãßõ»çÇ×°ú °á·Ð
  • ÁÖ¿ä ÅõÀÚ ±âȸ
  • ÁÖ¿ä ¼º°ø Àü·«

Á¦5Àå À§Çè Æò°¡ : COVID-19ÀÇ ¿µÇâ

    • ¾÷°è¿¡ ´ëÇÑ COVID-19ÀÇ ÀüüÀûÀÎ ¿µÇâ Æò°¡
    • COVID-19 ÀÌÀü¡¤COVID-19 ÀÌÈÄ ½ÃÀå ½Ã³ª¸®¿À

Á¦6Àå ¼¼°èÀÇ ¼öÀÇ Á¾¾çÇÐ ½ÃÀå : Ä¡·áº°

  • ½ÃÀå ÇöȲ
  • ½ÇÀû¡¤ÀáÀ缺 ºÐ¼® : Ä¡·áº°
  • ÃßÁ¤°ú ¿¹Ãø : Ä¡·áº°(2018-2028³â)
  • ÇÏÀ§ ºÎ¹® ºÐ¼®
    • ¼ö¼ú
    • ¹æ»ç¼± Ä¡·á
    • È­Çпä¹ý
    • ¸é¿ª¿ä¹ý
    • ±âŸ

Á¦7Àå ¼¼°èÀÇ ¼öÀÇ Á¾¾çÇÐ ½ÃÀå : µ¿¹° Á¾·ùº°

  • ½ÃÀå ÇöȲ
  • ½ÇÀû¡¤ÀáÀ缺 ºÐ¼® : µ¿¹° Á¾·ùº°
  • ÃßÁ¤°ú ¿¹Ãø : µ¿¹° Á¾·ùº°(2018-2028³â)
  • ÇÏÀ§ ºÎ¹® ºÐ¼®
    • °³
    • °í¾çÀÌ

Á¦8Àå ¼¼°èÀÇ ¼öÀÇ Á¾¾çÇÐ ½ÃÀå : ¾Ï Á¾·ùº°

  • ½ÃÀå ÇöȲ
  • ½ÇÀû¡¤ÀáÀ缺 ºÐ¼® : ¾Ï Á¾·ùº°
  • ÃßÁ¤°ú ¿¹Ãø : ¾Ï Á¾·ùº°(2018-2028³â)
  • ÇÏÀ§ ºÎ¹® ºÐ¼®
    • ¸²ÇÁÁ¾
    • ºñ¸¸¼¼Æ÷Á¾
    • À¯¼±¾Ï¡¤ÆíÆò»óÇǾÏ
    • ±âŸ

Á¦9Àå ¼¼°èÀÇ ¼öÀÇ Á¾¾çÇÐ ½ÃÀå : Áö¿ª ºÐ¼®

  • Áö¿ª ½ÃÀå ÇöȲ
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´ ÇöȲ
    • ¿µ±¹
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ÀÌÅ»¸®¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç ÇöȲ
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • È£ÁÖ
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä« ÇöȲ
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
  • ±âŸ Áö¿ª

Á¦10Àå °æÀï Á¤º¸

  • ÁÖ¿ä ½ÃÀå Àü·«
  • ±â¾÷ °³¿ä
    • PetCure Oncology
    • Zoetis
    • Karyopharm Therapeutics, Inc.
    • Varian Medical Systems
    • Accuray Incorporated
    • Boehringer Ingelheim GmbH
    • Elanco
    • One Health
    • Regeneus Ltd.
    • Morphogenesis, Inc

Á¦11Àå Á¶»ç °úÁ¤

KSM 22.06.29

Global Veterinary Oncology Market is valued approximately USD 207.5 million in 2021 and is anticipated to grow with a healthy growth rate of more than 12.1% over the forecast period 2022-2028. Veterinary oncology is the treatment of cancer-stricken pets in order to improve their quality of life. One of the most common causes of mortality in pets is cancer. Skin cancer and bone cancer are more common in dogs and cats. Due to constant exposure of animal skin to UV rays, skin tumors are the most prevalent and often diagnosed cancer in domestic animals. Veterinarians utilize the HHHHHMM scale to assess the quality of life of pet owners before making treatment decisions for diseases like cancer. The rising prevalence of cancer in the pet population, together with the increased use of veterinary cancer therapy as a treatment strategy, is driving market expansion. Another element driving market expansion is the global use of canine cancer registry to quantify cancer incidences. According to Frontiers in Veterinary Science in February 2019, The Swiss Canine Cancer Registry (SCCR) was used as a data source and was developed for future comparison research of canine and human cancers.. This database is also useful in reducing the occurrence of malignant tumours in the human population, resulting in market expansion. Researchers working on veterinary oncology studies are helping to propel the veterinary oncology market forward. For example, the University of Illinois conducted a study in August 2017 that involved more precise identification of metastasis (cancer spread throughout the body) in dogs with head and neck cancers. Furthermore, market participants are concentrating on new product development and strategic partnerships. For example, in 2018, AdvaVet, an Oasmia Pharmaceutical AB company, launched XR17 technology, which is based on nanoparticle formulation and makes a single Active Pharmaceutical Ingredient (API) or numerous APIs water soluble. It is a combined therapy that is also used to treat a variety of cancer conditions in pets. Major drivers driving the market are increased expenditure on animal healthcare in developed economies due to rising willingness to spend on pet healthcare by owners and government initiatives for veterinary cancer treatment. In addition, the American Veterinary Medical Association (AVMA) predicted in October 2019 that one out of every four dogs may have neoplasia at some point in their lifetimes. However, the high cost of veterinary cancer therapy, as well as side effects of oncology medications including as hair loss, decreased appetite, and vomiting, will stifle market expansion between 2022 and 2028.

The key regions considered for the global Veterinary Oncology Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America dominated the veterinary oncology market. Over the forecast period, the segment is expected to dominate the market. The growing focus on pet health, the presence of a large number of pet medicine manufacturing companies, and the rapid acceptance of novel pet care medications are all contributing to market growth. Furthermore, the government's increased support for pet oncology treatment in this region, as well as the existence of market behemoths in the oncology market, are boosting the market. The market in Asia Pacific is likely to develop over the forecast period as veterinarians become more aware of various treatment procedures for pets, veterinary healthcare infrastructure improves, and animal healthcare expenditure rises.

Major market player included in this report are:

PetCure Oncology

Zoetis

Karyopharm Therapeutics, Inc.

Varian Medical Systems

Accuray Incorporated

Boehringer Ingelheim GmbH

Elanco

One Health

Regeneus Ltd.

Morphogenesis, Inc

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Therapy

Surgery

Radiotherapy

Chemotherapy

Immunotherapy

Others

By Animal type:

Canine

Feline

By Cancer Type:

Lymphoma

Mast Cell Cancer

Mammary and Squamous Cell Cancer

Others

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

ROE

Asia Pacific

China

India

Japan

Australia

South Korea

RoAPAC

Latin America

Brazil

Mexico

Rest of the World

Furthermore, years considered for the study are as follows:

Historical year - 2018, 2019, 2020

Base year - 2021

Forecast period - 2022 to 2028

Target Audience of the Global Veterinary Oncology Market in Market Study:

Key Consulting Companies & Advisors

Large, medium-sized, and small enterprises

Venture capitalists

Value-Added Resellers (VARs)

Third-party knowledge providers

Investment bankers

Investors

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2028 (USD Million)
    • 1.2.1. Veterinary Oncology Market, by Region, 2020-2028 (USD Million)
    • 1.2.2. Veterinary Oncology Market, by Therapy, 2020-2028 (USD Million)
    • 1.2.3. Veterinary Oncology Market, by Animal Type, 2020-2028 (USD Million)
    • 1.2.4. Veterinary Oncology Market, by Cancer Type, 2020-2028 (USD Million)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Veterinary Oncology Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Scope of the Study
    • 2.2.2. Industry Evolution
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Veterinary Oncology Market Dynamics

  • 3.1. Veterinary Oncology Market Impact Analysis (2020-2028)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Increasing pervasiveness of cancer in the pet population
      • 3.1.1.2. Growing expenditure on animal healthcare
    • 3.1.2. Market Challenges
      • 3.1.2.1. High cost of veterinary cancer therapy
      • 3.1.2.2. Side effects of oncology medications including as hair loss, decreased appetite, and vomiting
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Increasing number of veterinary clinical studies for evaluating safety and efficacy of different oncologic treatments in pets.
      • 3.1.3.2. Supportive government initiatives pertinent to veterinary cancer treatment

Chapter 4. Global Veterinary Oncology Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
    • 4.1.6. Futuristic Approach to Porter's 5 Force Model (2018-2028)
  • 4.2. PEST Analysis
    • 4.2.1. Political
    • 4.2.2. Economical
    • 4.2.3. Social
    • 4.2.4. Technological
  • 4.3. Investment Adoption Model
  • 4.4. Analyst Recommendation & Conclusion
  • 4.5. Top investment opportunity
  • 4.6. Top winning strategies

Chapter 5. Risk Assessment: COVID-19 Impact

    • 5.1.1. Assessment of the overall impact of COVID-19 on the industry
    • 5.1.2. Pre COVID-19 and post COVID-19 Market scenario

Chapter 6. Global Veterinary Oncology Market, by Therapy

  • 6.1. Market Snapshot
  • 6.2. Global Veterinary Oncology Market by Therapy, Performance - Potential Analysis
  • 6.3. Global Veterinary Oncology Market Estimates & Forecasts by Therapy 2018-2028 (USD Million)
  • 6.4. Veterinary Oncology Market, Sub Segment Analysis
    • 6.4.1. Surgery
    • 6.4.2. Radiotherapy
    • 6.4.3. Chemotherapy
    • 6.4.4. Immunotherapy
    • 6.4.5. Others

Chapter 7. Global Veterinary Oncology Market, by Animal Type

  • 7.1. Market Snapshot
  • 7.2. Global Veterinary Oncology Market by Animal Type, Performance - Potential Analysis
  • 7.3. Global Veterinary Oncology Market Estimates & Forecasts by Animal Type 2018-2028 (USD Million)
  • 7.4. Veterinary Oncology Market, Sub Segment Analysis
    • 7.4.1. Canine
    • 7.4.2. Feline

Chapter 8. Global Veterinary Oncology Market, by Cancer Type

  • 8.1. Market Snapshot
  • 8.2. Global Veterinary Oncology Market by Cancer Type, Performance - Potential Analysis
  • 8.3. Global Veterinary Oncology Market Estimates & Forecasts by Cancer Type 2018-2028 (USD Million)
  • 8.4. Veterinary Oncology Market, Sub Segment Analysis
    • 8.4.1. Lymphoma
    • 8.4.2. Mast Cell Cancer
    • 8.4.3. Mammary and Squamous Cell Cancer
    • 8.4.4. Others

Chapter 9. Global Veterinary Oncology Market, Regional Analysis

  • 9.1. Veterinary Oncology Market, Regional Market Snapshot
  • 9.2. North America Veterinary Oncology Market
    • 9.2.1. U.S. Veterinary Oncology Market
      • 9.2.1.1. Therapy breakdown estimates & forecasts, 2018-2028
      • 9.2.1.2. Animal Type breakdown estimates & forecasts, 2018-2028
      • 9.2.1.3. Cancer Type breakdown estimates & forecasts, 2018-2028
    • 9.2.2. Canada Veterinary Oncology Market
  • 9.3. Europe Veterinary Oncology Market Snapshot
    • 9.3.1. U.K. Veterinary Oncology Market
    • 9.3.2. Germany Veterinary Oncology Market
    • 9.3.3. France Veterinary Oncology Market
    • 9.3.4. Spain Veterinary Oncology Market
    • 9.3.5. Italy Veterinary Oncology Market
    • 9.3.6. Rest of Europe Veterinary Oncology Market
  • 9.4. Asia-Pacific Veterinary Oncology Market Snapshot
    • 9.4.1. China Veterinary Oncology Market
    • 9.4.2. India Veterinary Oncology Market
    • 9.4.3. Japan Veterinary Oncology Market
    • 9.4.4. Australia Veterinary Oncology Market
    • 9.4.5. South Korea Veterinary Oncology Market
    • 9.4.6. Rest of Asia Pacific Veterinary Oncology Market
  • 9.5. Latin America Veterinary Oncology Market Snapshot
    • 9.5.1. Brazil Veterinary Oncology Market
    • 9.5.2. Mexico Veterinary Oncology Market
  • 9.6. Rest of The World Veterinary Oncology Market

Chapter 10. Competitive Intelligence

  • 10.1. Top Market Strategies
  • 10.2. Company Profiles
    • 10.2.1. PetCure Oncology
      • 10.2.1.1. Key Information
      • 10.2.1.2. Overview
      • 10.2.1.3. Financial (Subject to Data Availability)
      • 10.2.1.4. Therapy Summary
      • 10.2.1.5. Recent Developments
    • 10.2.2. Zoetis
    • 10.2.3. Karyopharm Therapeutics, Inc.
    • 10.2.4. Varian Medical Systems
    • 10.2.5. Accuray Incorporated
    • 10.2.6. Boehringer Ingelheim GmbH
    • 10.2.7. Elanco
    • 10.2.8. One Health
    • 10.2.9. Regeneus Ltd.
    • 10.2.10. Morphogenesis, Inc

Chapter 11. Research Process

  • 11.1. Research Process
    • 11.1.1. Data Mining
    • 11.1.2. Analysis
    • 11.1.3. Market Estimation
    • 11.1.4. Validation
    • 11.1.5. Publishing
  • 11.2. Research Attributes
  • 11.3. Research Assumption
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦